PMID- 12584214
OWN - NLM
STAT- MEDLINE
DCOM- 20030411
LR  - 20191210
IS  - 0017-5749 (Print)
IS  - 1458-3288 (Electronic)
IS  - 0017-5749 (Linking)
VI  - 52
IP  - 3
DP  - 2003 Mar
TI  - 18F-fluoro-deoxy-glucose positron emission tomography (18F-FDG-PET) for 
      assessment of enteropathy-type T cell lymphoma.
PG  - 347-51
AB  - BACKGROUND AND AIMS: Enteropathy-type T cell lymphoma (ETCL) represents a 
      relatively rare disease, accounting for less than 1% of non-Hodgkin's lymphomas. 
      ETCL is an aggressive lymphoma which may either present de novo or arise in the 
      context of longstanding or untreated coeliac disease (CD). The aim of this study 
      was to evaluate the potential of 18F-fluoro-deoxy-glucose positron emission 
      tomography (18F-FDG-PET) for imaging of ETCL. Furthermore, we wished to evaluate 
      whether the presence of CD might provide a potential diagnostic obstacle to 
      imaging of lymphoma due to unspecific 18F-FDG uptake and whether accumulation of 
      18F-FDG within the gut correlates with activity of CD. PATIENTS AND METHODS: We 
      retrospectively analysed patients with ETCL and individuals suffering from CD 
      undergoing 18F-FDG-imaging at our PET unit. Material for histological 
      reassessment by a reference pathologist had to be available for inclusion of 
      patients in the analysis. Whole body 18F-FDG-PET scans were performed 40 minutes 
      following injection of 300-380 MBq of 18F-FDG. Images were reconstructed 
      iteratively. In areas with focally elevated FDG uptake and in case of diffusely 
      elevated intestinal 18F-FDG accumulation, standard uptake values (SUVs) were 
      calculated. RESULTS: During a period of two years, five patients (one male, four 
      female) with a mean age of 56.4 years (range 44-62) with a diagnosis of ETCL 
      underwent 18F-FDG-PET. Four of these patients were imaged before application of 
      cytotoxic treatment while one patient had regular PET scans for follow up. All 
      four patients undergoing pre-therapeutic imaging showed markedly elevated 
      intestinal 18F-FDG uptake, with a maximal SUV of 6.4-8.0 (mean 7.15 (SD 0.82)). 
      The patient imaged following surgery and cytotoxic therapy had no pathologic 
      18F-FDG uptake which was found to correlate with normal duodenal mucosa, as 
      evidenced by repeated biopsies and conventional imaging methods. During the same 
      time span, 12 patients (five male, seven female) with a mean age of 63.8 years 
      (range 42-82) suffering from CD were imaged. Four of these patients showed no 
      elevated intestinal 18F-FDG uptake while five had minor diffuse intestinal 
      18F-FDG accumulation with SUVs ranging between 2.2 and 4.6 (mean 3.4 (SD 0.89)). 
      In the remaining three patients with diffuse intestinal 18F-FDG uptake, no SUV 
      could be calculated. SUVs in patients with ETCL were remarkably higher than in 
      patients suffering from CD (p=0.011), irrespective of the activity of CD at the 
      time of imaging. CONCLUSION: In spite of the relatively small number of patients, 
      our results clearly indicate the potential value of 18F-FDG-PET for diagnosing 
      and imaging ETCL. In addition, the data also suggest that 18F-FDG-PET may lead to 
      early diagnosis in individuals developing ETCL in the context of longstanding CD. 
      This is due to the fact that 18F-FDG does not appear to significantly accumulate 
      in the gut of patients with CD, irrespective of disease activity.
FAU - Hoffmann, M
AU  - Hoffmann M
AD  - Department of Nuclear Medicine, Internal Medicine IV, University of Vienna, 
      Vienna, Austria. martha.hoffmann@akh-wien.ac.at
FAU - Vogelsang, H
AU  - Vogelsang H
FAU - Kletter, K
AU  - Kletter K
FAU - Zettinig, G
AU  - Zettinig G
FAU - Chott, A
AU  - Chott A
FAU - Raderer, M
AU  - Raderer M
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - England
TA  - Gut
JT  - Gut
JID - 2985108R
RN  - 0 (Radiopharmaceuticals)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Celiac Disease/*complications/diagnostic imaging
MH  - Female
MH  - *Fluorodeoxyglucose F18
MH  - Humans
MH  - Intestinal Neoplasms/*diagnostic imaging/etiology
MH  - Intestine, Small/diagnostic imaging
MH  - Lymphoma, T-Cell/*diagnostic imaging/etiology
MH  - Male
MH  - Middle Aged
MH  - Radiopharmaceuticals
MH  - Retrospective Studies
MH  - Tomography, Emission-Computed/*methods
PMC - PMC1773540
EDAT- 2003/02/14 04:00
MHDA- 2003/04/12 05:00
PMCR- 2006/03/01
CRDT- 2003/02/14 04:00
PHST- 2003/02/14 04:00 [pubmed]
PHST- 2003/04/12 05:00 [medline]
PHST- 2003/02/14 04:00 [entrez]
PHST- 2006/03/01 00:00 [pmc-release]
AID - 0520347 [pii]
AID - 10.1136/gut.52.3.347 [doi]
PST - ppublish
SO  - Gut. 2003 Mar;52(3):347-51. doi: 10.1136/gut.52.3.347.